bonyf NV Cancels Planned Capital Increase Following Positive Strategic Developments

bonyf NV / Key word(s): Financing/Corporate Action bonyf NV Cancels Planned Capital Increase Following Positive Strategic Developments 05-Sep-2025 / 10:51 CET/CEST bonyf NV Cancels Planned Capital Increase Following Positive Strategic Developments

 

Knokke-Heist (Belgium), 5 September 2025, 6:00 a.m.; bonyf NV (Ticker: MLBON), a leader in dental consumer goods, professional dental consumables and dermatological solutions, announces that the capital increase previously under consideration has been cancelled, following a series of significant and positive business developments.

Recent successful negotiations with strategic partners have opened new commercial opportunities, strengthening the company’s financial and strategic outlook. In parallel, bonyf has received favorable confirmation from its Medical Device auditors, Dekra Germany, regarding the upcoming launch of its innovative product, PerioCream.

This breakthrough product, based on bonyf’s proprietary NitrAdine technology, has now received the green light for early market entry. As a result, bonyf expects a faster-than-anticipated global roll-out, which will generate future revenue streams supporting the company’s international growth ambitions.

In addition, the completion of an in-depth clinical study with outstanding results has further validated PerioCream’s efficacy and market potential, reinforcing bonyf’s R&D leadership in oral care innovation.

Furthermore, advanced negotiations with bonyf’s U.S. partner are progressing constructively, with preparations underway for FDA registration. This marks an important milestone for expanding into the U.S. market, one of the world’s largest and most dynamic healthcare markets.